Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical leader developing precision oncology therapies through synthetic lethality approaches. This page provides investors and researchers with timely updates on the company’s progress in targeting DNA damage response pathways in solid tumors.
Access authoritative reporting on Aprea’s pipeline developments, including its ATRN-119 and APR-1051 programs. Our curated news collection covers clinical trial milestones, regulatory updates, and strategic collaborations, helping stakeholders track innovations in targeted cancer therapies.
Key content includes updates on phase 1/2 trial results, FDA communications, intellectual property expansions, and research partnerships. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic area.
Bookmark this page for centralized access to Aprea’s latest scientific advancements and corporate announcements. Check regularly for developments in next-generation oncology treatments leveraging synthetic lethality mechanisms.
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focusing on novel cancer therapeutics, has announced an underwritten public offering of its common stock. All shares in this offering will be sold by Aprea, and the underwriter is granted a 30-day option to purchase an additional 15% of the shares. The offering is subject to market conditions. This move is part of Aprea's strategy to further advance its synthetic lethality-based therapies targeting DNA damage response pathways, including its clinical-stage ATR inhibitor program. Maxim Group LLC is the sole book-running manager for this offering.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced receiving an award notification from the National Cancer Institute (NCI) for developing a first-in-class combination of DNA damage response inhibitors to treat high-grade serous ovarian cancer (HGSOC). The funding totals up to $1,996,571 over two years, contingent on project progress. HGSOC claims approximately 125,000 lives globally each year, with many cases harboring genetic mutations. Aprea will initiate a first-in-human clinical trial for its ATR inhibitor, ATRN-119, and its WEE1 inhibitor, ATRN-W1051. The grant aims to evaluate the efficacy of both agents against HGSOC.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a one-for-twenty reverse stock split effective February 10, 2023, to comply with Nasdaq listing requirements. This move reduces the outstanding shares from approximately 53.6 million to about 2.7 million, while keeping the number of authorized shares unchanged. The adjusted trading on Nasdaq began on February 13, 2023, under the same symbol, APRE. All stockholders are affected uniformly without changes to their percentage ownership, except due to fractional shares, which will be sold with cash payments made to stockholders. The exchange agent for this process is Computershare Trust Co., N.A.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the appointment of John Hamill as Chief Financial Officer, bringing over 30 years of finance experience in the pharmaceutical and biopharmaceutical sectors. Hamill's background includes leadership roles in financial, administrative, and IT functions. He succeeds Scott Coiante, who will stay until March 31, 2023, to ensure a smooth transition. The company is at a pivotal moment as it advances its ATR inhibitor through Phase 1 clinical trials, with management expressing optimism about improving cancer treatments and future growth.
Aprea Therapeutics (Nasdaq: APRE) announced its participation in the 6th Annual DDR Inhibitors Summit in Boston from January 24-26, 2023. CEO Oren Gilad will lead a panel on validating newer targets for clinical trials and deliver presentations on related topics. Key sessions include discussions on DDR inhibitors and the proprietary Repli-Biom platform for identifying biomarkers. The event will feature notable presentations by both Oren Gilad and Eric Brown, with discussions scheduled to focus on clinical challenges and targeting biomarkers.
Aprea is advancing cancer therapeutics targeting DNA damage response pathways, with lead program ATRN-119.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the dosing of the first patient in its Phase 1/2a clinical trial of ATRN-119, an ATR inhibitor aimed at treating cancers with DNA damage response mutations. The trial will evaluate ATRN-119's tolerability, pharmacokinetics, and efficacy in advanced solid tumors. Preclinical studies indicate that ATRN-119 has shown potent anti-proliferative effects and the potential for lower toxicity compared to other ATR inhibitors. The company plans to share preliminary data from the trial throughout 2023.
Aprea Therapeutics (Nasdaq: APRE) reported Q3 2022 financial results, highlighting a net loss of $4.0 million ($0.12 per share), a reduction from $9.5 million ($0.45 per share) in Q3 2021. As of September 30, 2022, cash and cash equivalents totaled $33.1 million, adequate to support operations through 2023. R&D expenses dropped significantly to $1.1 million from $6.0 million year-over-year. The company is advancing its ATRN-119 clinical trial for cancer treatment, with plans to open additional sites soon.
Aprea Therapeutics (Nasdaq: APRE) announced the presentation of its abstract on the WEE1 inhibitor ATRN-W1051 at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series held on September 21, 22, 28, and 29, 2022. CEO Oren Gilad highlighted ATRN-W1051's potential as a selective WEE1 inhibitor with favorable pharmacokinetic properties, showing promising anti-proliferative activity in various cancer cell lines and tumor growth inhibition in ovarian cancer models. The company plans to complete IND-enabling studies and initiate clinical programs soon.
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:30 p.m. ET. The presentation will cover Aprea’s synthetic lethality and DNA damage response (DDR) pipeline, highlighting:
- ATRN-119, a Phase 1-ready small molecule ATR inhibitor
- ATRN-W1051, a preclinical WEE1 inhibitor
- Repli-Biom, a discovery platform for precision oncology
- Eprenetapopt, a clinical-stage p53 reactivator
The presentation can be accessed on Aprea's website.
Aprea Therapeutics (Nasdaq: APRE) reported its Q2 2022 financial results, revealing a net loss of $98.3 million or $4.34 per share, significantly higher than the $10.3 million loss in Q2 2021. Cash and cash equivalents declined to $39.1 million by June 30, 2022, from $53.1 million at the end of 2021. R&D expenses remained stable at $6.8 million. The company completed the acquisition of Atrin Pharmaceuticals, heightening its focus on DNA damage response therapeutics. Upcoming clinical trials for ATRN-119 and APR-548 are expected to progress through late 2022.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
